Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Arne Claeys

Publications & Research Data

Awards & Distinctions

14 Results

2026

RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells

Joachim SiawArne ClaeysWei-Yun LaiMarcus BorenäsElien HilgertSarah-Lee BekaertEllen SandersIrem KayaJo Van DorpeFranki Speleman et al.

A1 Journal Article in ISCIENCE

2025

Spatial transcriptomics exploration of the primary neuroblastoma microenvironment in archived FFPE samples unveils novel paracrine interactions

Joachim SiawPeter MerseburgerMarcus BorenäsCaroline JanssonJenny KarlssonArne ClaeysEva JennischeDan E LindDavid Gisselsson NordRuth H Palmer et al.

A1 Journal Article in JOURNAL OF PATHOLOGY

2024

Effects of hyperthermia on cisplatin tissue penetration and gene expression in peritoneal metastases : results from a randomized trial in ovarian cancer

Jesse DemuytereCharlotte CarlierTom Van HeldenJoke BelzaFrank VanhaeckeFeifan XieAn VermeulenJoseph WeertsJürgen ThomaleHannelore Denys et al.

A1 Journal Article in BRITISH JOURNAL OF SURGERY

MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma

Arne ClaeysJimmy Van den Eynden

A2 Journal Article in COMMUNICATIONS MEDICINE

2023

A computational exploration of MHC-based immune selection signals in large cancer genome sequencing datasets

Arne ClaeysJimmy Van den EyndenKathleen Marchal

Benchmark of tools for in silico prediction of MHC class I and class II genotypes from NGS data

Arne ClaeysPeter MerseburgerJasper StautKathleen MarchalJimmy Van den Eynden

A1 Journal Article in BMC GENOMICS

MHC class I and class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma

Jimmy Van den EyndenArne Claeys

Preclinical exploration of the DNA Damage Response pathway using the interactive neuroblastoma cell line explorer CLEAN

Jonatan Linus GabrePeter MerseburgerArne ClaeysJoachim SiawSarah-Lee BekaertFranki SpelemanBengt HallbergRuth H. PalmerJimmy Van den Eynden

Quantification of neoantigen-mediated immunoediting in cancer evolution : letter

Arne ClaeysJimmy Van den Eynden

A1 Journal Article in CANCER RESEARCH

2022

A clinically annotated post-mortem approach to study multi-organ somatic mutational clonality in normal tissues

Tom LuijtsKerryn ElliottJoachim SiawJoris Van de VeldeElien BeylsArne ClaeysTim LammensErik LarssonWouter WillaertAnne Vral et al.

A1 Journal Article in SCIENTIFIC REPORTS

Benchmark of tools for in silico prediction of MHC class I and class II genotypes from NGS data

Arne ClaeysJasper StautPeter MerseburgerKathleen MarchalJimmy Van den Eynden

2021

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation

Marcus BorenäsGanesh UmapathyWei‐Yun LaiDan E LindBarbara WitekJikui GuanPatricia Mendoza‐GarciaTafheem MasudiArne ClaeysTzu‐Po Chuang et al.

A1 Journal Article in EMBO JOURNAL

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models

Joanna SzydzikDan E. LindBadrul ArefinYeshwant KurheGanesh UmapathyJoachim Tetteh SiawArne ClaeysJonatan Linus GabreJimmy Van den EyndenBengt Hallberg et al.

A1 Journal Article in NATURE COMMUNICATIONS

Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals

Arne ClaeysTom LuijtsKathleen MarchalJimmy Van den Eynden

A1 Journal Article in PLOS Genetics